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Abstract
Background: MicroRNAs (miRNAs) are a novel class of gene expression regulators implicated in
cancer biology. Neuroblastoma (NB) is an embryonal tumour consisting of neural crest-derived
undifferentiated cells and is characterised by variable clinical courses ranging from spontaneous
regression to therapy-resistant progression. Recent advances identified a subset of miRNAs with
putative function in NB biology. However, the full repertoire of miRNAs expressed in NBs is not
available.
Results: We describe miRNA profiles of 13 NB specimens and 2 NB cell lines as determined by
miRNA cloning. A total of 3153 sequences were sequenced and analysed by a miRNA prediction
tool (miRpredict). Our library covered 27% miRNAs known to date. 39 reads corresponding to 25
individual sequences were classified as novel miRNAs, including miRNA* species of 10 known
miRNAs. Expression of 5 new miRNA* forms and 8 individual sequences was supported by
Northern blotting. Most of the novel miRNA genes are not related to each other and do not share
homology with the annotated sequences in the public miRNA database, but they are conserved
within mammals or have close homologues in primates genomes.
Conclusion: We provide evidence for 29 new miRNA and miRNA-like sequences (24 novel
sequences and 5 miRNAs discovered initially in other species). Some of these newly identified
sequences reside within frequently altered chromosomal regions in NB tumours and may play a
role in NB biology.
Background
Neuroblastoma is the second commonest solid cancer in
young children accounting for 9% of all childhood can-
cers. It is characterised by a heterogeneous clinical behav-
iour ranging from spontaneous regression in 10% of all
cases to rapid progression with unfavourable prognosis
[1,2]. Amplified MYCN leading to high MYCN mRNA and
protein levels plays an important role in NB biology and
is used as a powerful prognostic marker in NB risk stratifi-
cation. In addition, several other genetic abnormalities,
including gain of 17q, 11q and 1p deletion have been
associated with an aggressive NB phenotype [3]. Further,
microarray technology has been used to study gene
expression profiles in primary NBs. Patterns of differen-
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as gene expression classifiers have emerged allowing a bet-
ter prediction of patient's outcome than established risk
markers [4,5].
MiRNAs that regulate gene expression at the posttranscrip-
tional level have been described to play a role in carcino-
genesis via executing oncogenic or tumour suppressive
functions [6-8]. For example, let-7 miRNAs are down-reg-
ulated in lung cancer and are known to target proto-onco-
gene RAS transcripts [9]. Mir-17-92 cistron is to be
overexpressed in human lung cancer and upregulated by
c-Myc [10,11]. miR-15 and miR-16 are frequently deleted
and down-regulated in chronic lymphocytic leukemias
[12]. The expression profiles of a small set of miRNAs
could be used to classify different types of cancer [13-15].
More recently, profiling of a subset of known miRNAs in
neuroblastoma specimens suggested that MYCN acts as a
regulator of miRNAs [16].
However, the full repertoire of miRNAs expressed in dif-
ferent cancer types, including neuroblastoma, is not yet
available. Prognosis-relevant miRNAs with putative onco-
genic functions could have been missed in previous clon-
ing efforts due to their silent state or low-expression.
There is evidence to date that neural lineage cells are par-
ticularly rich in miRNA diversity [17-19]. In this study, we
aimed at cloning novel miRNAs from NB cell lines and NB
specimens that may have a role in NB biology. Here, we
present the analysis of small RNA libraries derived from
neuroblastoma tumour specimens and cell lines and sug-
gest several novel miRNAs. Some of these miRNAs reside
within loci of cancer-associated rearrangements and are of
special interest for future studies.
Results and discussion
MiRNA cloning and abundance of previously annotated 
miRNAs
For NB miRNA library construction, we used RNA derived
from 13 tumour samples as well as two neuroblastoma
cell lines, SH-EP (MYCN single-copy) and Kelly (MYCN
amplified). We followed the guidelines of Lau et al. ensur-
ing that only those RNA species were cloned which con-
tained 5'-phosphate [20]. The following cohort of
tumours was used for cloning: four MYCN amplified,
three stage 4S MYCN single-copy, two stage 4 MYCN sin-
gle-copy and four stage 1 MYCN single-copy tumours
(Table 1).
Approximately 80 clones per specimen or cell line were
sequenced. After linker unmasking, 3185 small RNA
cDNA sequences were subjected to further analyses. The
percentage of "not-known-miRNA" sequences varied
from 18% to 60% which corresponds to previously
described fractions of other non-coding RNAs, redundant
sequences as well as novel miRNAs in small RNA libraries
[17,21]. Our cloning project covered 27% (128 miRNAs)
of miRNAs currently present in the public miRNA registry
(miRBase 9.1) [22]. 39 miRNAs were represented by only
one read. On the other hand, mir-124a (with three loci on
8p23.1, 8q12.3, 20q13.33) and -125b (11q24.1 and
21q21.1) yielded 113 and 132 reads, respectively (see
Additional File 1). MiRNA cloning was established as an
independent semi-quantitative method to evaluate
miRNA abundance [23]. This allowed us to conclude that
mir-124a and -125b were the most abundant ones. Both
miRNAs are considered as having neuronal specificity
[24,25]. Among the most frequently identified miRNAs
was mir-21 (17q23.2), a transcript with putative anti-
apoptotic and tumour promoting activities [8]. A differ-
ence in the abundance of certain miRNAs was observed in
MYCN-amplified and non-amplified specimens. In
MYCN-amplified tumours/cell line, we observed a higher
abundance of miRNAs from the mir-17/92 cluster
(13q31.3) that is known to be up-regulated by c-Myc. The
average numbers for hsa-mir-17-5p and hsa-mir-20a
reads in MYCN-amplified and single-copy specimens
were 5 versus 0.8 and 3.6 versus 0.6, respectively. A group
of miRNA sequences that clustered on chromosome 19
was exclusively found in the library of the MYCN ampli-
fied tumour, MYCNAMP_NB2. This argues for a cistronic
manner of transcription of this group of miRNA
sequences. Beside annotated human miRNAs we have
cloned 5 sequences that have been originally identified in
rat and mouse (see Additional File 1).
Identification and validation of new miRNAs
After removing redundant sequences and the sequences
derived from other non-coding RNAs, the remaining pool
was checked in silico for the detection of the putative
miRNA precursors using miRPredict (see Methods). This
analysis yielded 25 distinct sequences (39 reads) which
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sequences were miRNA* forms of previously annotated
miRNA precursors (Table 2). Hsa-mir-594 was cloned by
the Velculescu group, but then excluded from miRBase
due to overlap with a tRNA gene [26]. Cloning of the 594*
species described here provides evidence for the miRNA
nature of these sequences.
Other 15 sequences represent novel small RNAs which
have not been annotated. Two novel sequences were
found adjacent to chromosomal localisations of known
miRNAs: MYCNSC_NB5_330 within a miRNA cluster on
chromosome 14 as well as MYCNAMP_NB2_61 within a
miRNA cluster on chromosome 19 (Table 3). Phyloge-
netic conservation was determined for each putative
miRNA and its surrounding with respect to chimpanzee,
macaque, opossum, mouse, rat, dog, bull and chicken
genomes (see Additional File 2). We found that the cloned
sequences with the exception of MYCNAMP_NB4_70 are
conserved either within all chosen species or primates.
The non-conserved MYCNAMP_NB4_70 sequence seems
to be the result of a short duplication within an intron of
the DPP10 transcript (Fig. 1). However, homologous
regions in chimpanzee and macaque genomes are also
able to form hairpins which might give rise to miRNAs.
Novel miRNAs do not share any homology with each
other and therefore do not comprise a family. Searching
against miRBase revealed that none of the new miRNAs
are related to the annotated miRNAs in miRBase, except of
one sequence, MYCNAMP_NB2_5, that is homologous to
hsa-mir-151 and -28. Analysis of genomic locations of the
individual miRNAs showed that 5 of them are localized in
extragenic regions. 8 sequences are found within introns
of coding transcripts. MYCNSC_NB5_64, classified as a
miRNA by miRpredict, is found within a predicted U5
gene which reduces reliability of this sequence as a
miRNA (Table 3). The likely precursors of the novel miR-
NAs (Fig. 2) may be subdivided into two subgroups: struc-
tures with typical hairpin or borderline precursors. The
latter subgroup has features divergent from a canonical
miRNA hairpin, such as bulges (KELLY_276,
MYCNSC_NB2_148), short stem (MYCNSC_NB5_41) or
"oscillating" hairpin (MYCNAMP_NB4_70), where the
candidate miRNA can reside on the 5' or 3'-arm. Lui et al.
reported the cloning of a subset of non-canonical miR-
NAs, however the relevance of such RNAs to the classical
miRNA pathway remains to be determined [27].
Based on the data listed above, we subjected 24 new miR-
NAs to Northern blot validation using biotinylated
probes. Borderline case MYCNSC_NB5_64 sequences
were not further examined. The expression of each puta-
tive miRNA was checked in a panel of human tissues,
including different tumour specimens, normal brain,
adrenal gland, spleen and skeletal muscle tissues. 5 of 10
cloned miRNA* sequences and 8 sequences from individ-
ual hairpins were Northern blot positive (Fig. 3). The
other 11 sequences remained undetectable (data not
shown). The probe for MYCNSC_NB5_41 yielded a signal
around 30 nt which is higher than the estimated sequence
size. The probes for CONTIG_CHR_9,
MYCNSC_NB5_237 and MYCNAMP_NB2_5 yielded sev-
eral bands different in length by 1–3 nucleotides. Some
known miRNAs show such patterns in Northern blot
analyses and intermediate products of miRNA maturation
have been observed, but there is no comprehensive expla-
nation for these results [19,28,29]. In normal tissues,
Northern blot-positive miRNAs are preferentially
expressed in brain, skeletal muscle tissue and adrenal
gland, being less frequently expressed in spleen. The
detection of miRNAs in skeletal muscle might be due to
the presence of motor neurons. Several miRNAs showed
differential expression in normal versus tumour speci-
mens: CONTIG_CHR_9, KELLY_276, MYCNAMP_NB2_5
were expressed in tumours, but not in normal tissues. On
the other hand, we did not find MYCNAMP_NB2_61
miRNA in tumour specimens, but we found strong expres-
sion of this sequence in brain.
Table 2: Novel human miRNA* sequences identified by cloning from NB





HSA-MIR-188* ctcccacatgcagggtttgca Xp11.22 - 1 3'-arm
HSA-MIR-106b* ccgcactgtgggtacttgctgc 7q22.1 + 5 3'-arm
HSA-MIR-423* tgaggggcagagagcgaga 17q11.2 + 1 5'-arm
HSA-MIR-594* cctaagccagggattgtgggtt 7q34 - 1 5'-arm
HSA-MIR-342* aggggtgctatctgtgattgagg 11q32.2 + 1 5'-arm
HSA-MIR-490* ccatggatctccaggtgggt 7q33 - 2 5'-arm
HSA-MIR-361* cccccaggtgtgattctgatttg Xq21.1 + 3 3'-arm
HSA-MIR-28* cactagattgtgagctcctgga 3q28 - 1 3'-arm
HSA-MIR-127* ctgaagctcagagggctctgat 14q32.31 - 1 5'-arm
HSA-MIR-214* tgcctgtctacacttgctgtgca 1q24.3 + 2 5'-arm
Notes give the information which hairpin arm expresses the miRNA* form.Page 3 of 7
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Recently, several studies have been performed aiming at
directional cloning of tissue/tumour specific miRNAs
[13,26,27]. The importance of such an approach is high-
lighted by the fact that patterns of novel miRNAs from
tumours of different lineages hardly overlap and may
include miRNAs with a functional role in tumourigenesis.
Our study provides evidence for 29 new human miRNAs
cloned from neuroblastoma. 5 of them were originally
cloned from other species and have not been annotated in
the human miRNA database. 10 sequences represent
miRNA* species of previously annotated sequences. 14
sequences, which have not been annotated before, are
suggested to be novel miRNAs. Some of these miRNAs are
found within regions of chromosomal rearrangements
associated with cancer. For example, new miRNAs on
9p21 residing within NB-related aberration region are of
special interest for future studies [30]. miRNA profiling of
MYCNAMP_NB4_70, a novel miRNA-like sequence resulting from a duplication eventFigure 1
MYCNAMP_NB4_70, a novel miRNA-like sequence resulting 
from a duplication event. Short sequences flanking 
MYCNAMP_NB4_70 were extracted from the human 
genome, as well as homologuous sequences from chimpan-
zee, macaque, mouse, rat and dog genomes and aligned. The 
bar indicates the MYCNAMP_NB4_70 sequence. The dupli-
cation is marked by a box.
Table 3: Novel human miRNA sequences identified by cloning from NB





MYCNAMP_NB2_5 aaggagcttacaatctagctggg 11q14.1 + 1 predicted gene
MYCNSC_NB2_148 acccagcaccccaggtttccacag 12q13.12 - 1 Tubulin-K-alpha-1
MYCNSC_NB5_330 taggacacatggtctacttct 14q32.31 + 1 within miRNA cluster
MYCNAMP_NB2_61 tcaaaactgaggggcattttct 19q13.42 + 4 within miRNA cluster
MYCNAMP_NB4_70 cctgtgttttgttggtagcctgtgttac 2q14.1 - 1 DPP10
MYCNSC_NB8_202 ccagacagaattctatgcactttc 3p12.3 - 1 KIAA0664
MYCNSC_NB5_41 tcaccccataaacacca 3p13 + 1 Extragenic
MYCNSC_NB5_281 tccattacactaccctgcctct 3p25.3 - 1 Plasma membrane calcium 
ATPase isoform 2
KELLY_276 tcgattcccacccctgacacca 4q13.1 + 1 Extragenic
MYCNSC_NB3_226 ctgccctggcccgagggaccga 5q31.2 - 1 Kelch-like-3
CONTIG_CHR_9 tgcaggaacttgtgagtctcc 9p21.1 + 4 Extragenic
MYCNSC_NB5_318 tggatttctttgtgaatca 9p21.1 + 1 Extragenic
MYCNAMP_NB2_241 cagggaggtgaatgtgat Xq21.2 - 1 Extragenic
MYCNSC_NB5_64 aagctaattttttgaggcc 15q22.31 NA 1 U5 predicted, borderline case
MYCNSC_NB2_237 gatgatgctgctgatgctg 8p23.1 + 1 Pin2-interacting protein X1
Notes include the information about genomic locations and additional sequence information.
Predicted secondary structures of the putative novel human miRNA precursorsFigure 2
Predicted secondary structures of the putative novel human 
miRNA precursors. Human genomic sequences upstream 
and downstream of the novel miRNAs were folded with the 
computer program RNAfold. Grey areas represent the 
cloned miRNA. a) miRNA with canonical hairpin. b) border-
line structures.Page 4 of 7
(page number not for citation purposes)
BMC Genomics 2008, 9:52 http://www.biomedcentral.com/1471-2164/9/52these novel sequences will allow us to clarify their rele-
vance in NB development, progression and regression.
Methods
Tumour specimens and cell culture
SH-EP and Kelly cells were cultured in RPMI supple-
mented with 10% fetal calf serum, glutamate and penicil-
lin/streptomycin. NB tumour samples were collected
prior to any cytoreductive treatment and were frozen
immediately until RNA was isolated. Written informed
consent was obtained from patients' parents for tissue
sampling. Genomic MYCN status was assessed in the ref-
erence laboratories of the German NB trial in Köln and
Heidelberg.
Small-RNA library construction and sequencing
Small-RNA fractions were directly isolated with the use of
the mirVana miRNA Isolation Kit (Ambion). 18–26 nt
RNA library construction was performed as described by
Lau and coworkers [20]. Sequencing was performed by
GATC BIOTECH (Konstanz, Germany).
Sequence analysis and prediction of novel miRNAs
Quality and vector trimming of sequences were per-
formed with Vector NTI software. After unmasking linker
sequences, inserts of ≥17 bp were analysed using miRPre-
dict, a miRNA prediction pipeline [31]. miRPredict com-
pares each potential miRNA to both known miRNAs and
to other non-coding RNAs (EnsEMBL RNA database,
Assembly 36) with a pattern-match algorithm using the
EMBOSS program fuzznuc [32]. Sequences corresponding
to other non-coding RNAs were discarded and the rest was
localised in the genome via Blast search. The genomic hit
together with additional 50 bases to both sides were
extracted as potential precursor miRNA. In case that more
than one localization in a contig was found, as indicated
by equal score and expectation values of the BLAST search,
all localizations were used for further processing. In the
precursor DNA, palindromic structures are recognized by
the program PALINDROME (EMBOSS package, allowing
4 mismatches in the stem, loop max. 40 bases, length
between 15 and 50). If a palindrome was found, the pal-
indromic region was folded with RNAFOLD (Vienna
package) to get the energy value and the input file for the
triplet SVM classifier [33,34]. The triplet SVM determines
the fold as miRNA-like palindrome (value +1), other pal-
indrome (value -1) or regions with more than one loop
(empty output).
To assess hairpin conservation, we extracted alignments of
putative miRNA precursors from chimpanzee, macaque,
mouse, rat, dog, cow, opossum and chicken genomes via
EnsEMBL. Extracted sequences were checked for hairpin
structures with the use of RNAfold, and aligned by RNA-
forester [35].
Northern blot analysis of newly cloned miRNAsFigur  3
Northern blot analysis of newly cloned miRNAs. N1...N10 – tumour samples; BR-Brain, AD-Adrenal gland, SK-Skeletal muscle, 
SP-Spleen. The positions of marker are indicated. U6 RNA was used as a loading control.Page 5 of 7
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Total RNA was isolated with TRIZOL reagent (Invitrogen).
30 micrograms of total RNA was loaded per lane and sep-
arated on 15% denaturing polyacrylamide gels, trans-
ferred by electroblotting to GeneScreen+ membranes
(Perkin Elmer). To check for non-radioactive probe specif-
icity, 250 pg of synthetic 5'-phosphorylated sequence
identical to the respective miRNA was loaded along with
5'-phosphorylated marker sequences (20 + 30 nt, 250 pg
each, see Additional Files 3 and 4). Blots were hybridized
overnight at 37°C with radioactively α-(32P) labeled DNA
oligo probes complementary to the cloned sequences in
Church buffer, washed twice with 2 × SSC, 0.1% SDS at
37°C, and exposed to films (Fuji Film). For non-radioac-
tive detection, blots were incubated with 3'-biotinylated
probes (10 ng/ml) and then processed with North2 South
Chemiluminescent Hybridization and Detection Kit
(Pierce). Prolonged washing was applied after incubation
with HRP-streptavidine conjugate.
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